Eli Lil­ly ver­sus the 800-pound go­ril­la in atopic der­mati­tis? It may just have a shot — at 2nd place

Eli Lil­ly turned a few heads when the mar­ket ma­jor bought out the IL-13 le­brik­izum­ab for $1.1 bil­lion a lit­tle more than 2 years ago. And late last year it kept up the rah-rah when CEO Dave Ricks tapped this drug as a top-5 drug in the late-stage pipeline.

Could El­li Lil­ly and Eu­ro­pean part­ner Almi­rall re­al­ly think they could take on the Il-13/IL-4 Dupix­ent, the 800-pound bi­o­log­ic go­ril­la in atopic der­mati­tis, from Re­gen­eron and Sanofi?

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER